Please provide your email address to receive an email when new articles are posted on . Lyu and colleagues analyzed electronic medical records data from 151 adults aged at least 45 years identified as ...

Shanghai Henlius Biotech and Organon have received permission from the Food and Drug Administration for Bildyos (denosumab-nxxp) injection 60 mg/ml and Bilprevda (denosumab-nxxp) injection 120 mg/1.7 ...

Delaying doses of denosumab after the first injection dramatically boosts the risk that patients with osteoporosis will suffer vertebral fractures, a new study confirms. Physicians say they are ...

Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related conditions. The Patels added, "With the addition of two denosumab ...

AUSTIN, Texas – One year of romosozumab (Evenity) followed by 1 year of denosumab (Prolia, Xgeva) was associated with improved bone mineral density (BMD) and lower fracture incidence compared with 2 ...

THOUSAND OAKS, Calif., June 1, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from a randomized, double-blind, placebo-controlled, multicenter Phase 3 study evaluating the treatment ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

On May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) ...

(RTTNews) - Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Bosaya ...